drugset
drugset / Trial / NCT04277910

A SAD/MAD Study to Evaluate the Safety, Tolerability, PK and PD of MT2004

NCT04277910 ↗

Phase 1 Completed 88 enrolled Xi'an Biocare Pharma Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single dose of MT2004 following oral single and multiple ascending dose administration.

Timeline

Start
2020-01-09
Primary completion
2021-04-30
Completion
2021-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator MT2004 Small molecule — Oral

Indications

No indication recorded.